Scott Louis Cohen

This inventor holds 11 USPTO granted patents and 1 published patent application and 4 EPO patents. Top assignee: Novartis Ag. Active years: 2012-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Scott Louis Cohen. Retrieved from https://idiyas.com/inventor/scott-louis-cohen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 1)

% Patents Active = 72.7

EPO Patents = 4 (Patent Applications = 7)

Average Co-Inventor Count = 5.6

ph-index = 3

Forward Citations = 15(Granted Patents)

Location History:

Cambridge, MA (US) (2014)
Peabody, MA (US) (2012 - 2020)
Burlington, MA (US) (2022)

Company Filing History:

11 out of 3,977

Novartis Ag

patents

Years Active: 2012-2022

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11466048 - 3' end caps, 5′ end caps and combinations thereof for therapeutic RNA (2022-10-11),

2. 10676499 - 3' end caps, 5′ end caps and combinations thereof for therapeutic RNA (2020-06-09),

3. 10112963 - Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors (2018-10-30),

4. 9789118 - Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof (2017-10-17),

5. 9498483 - 2,3,5-trisubstituted thiophene compounds and uses thereof (2016-11-22),

6. 9480693 - Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors (2016-11-01),

7. 9163040 - Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors (2015-10-20),

8. 9040690 - 2,3,5-trisubstituted thiophene compounds and uses thereof (2015-05-26),

9. 8697739 - Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof (2014-04-15),

10. 8394858 - Cyclohexane derivatives and uses thereof (2013-03-12),

11. 8324239 - Furopyridine compounds and uses thereof (2012-12-04),

Title: Scott Louis Cohen: Innovator in Therapeutic RNA Modifications

Introduction

Scott Louis Cohen is a prominent inventor based in Peabody, MA (US). He has made significant contributions to the field of therapeutic RNA through his innovative work. With a total of 11 patents to his name, Cohen has established himself as a key figure in the development of modified nucleic acids.

Latest Patents

Cohen's latest patents include advancements in 3' end caps, 5' end caps, and combinations thereof for therapeutic RNA. These disclosures relate to nucleic acids that contain modifications at the 5'-end, 3'-end, or both. The compounds developed can be used to create modified nucleic acids that exhibit improved expression, lower immunogenicity, and enhanced stability compared to their unmodified counterparts.

Career Highlights

Scott Louis Cohen is currently associated with Novartis AG, where he continues to push the boundaries of innovation in the pharmaceutical industry. His work focuses on enhancing the efficacy of therapeutic RNA, which has the potential to revolutionize treatment options for various diseases.

Collaborations

Cohen collaborates with notable colleagues such as David Weninger Barnes and Gregory Raymond Bebernitz. These partnerships contribute to the advancement of research and development in the field of therapeutic RNA.

Conclusion

Scott Louis Cohen's contributions to the field of therapeutic RNA through his innovative patents and collaborations highlight his importance as an inventor. His work continues to pave the way for advancements in medical treatments and therapies.

Profile summary based on public USPTO records.